Compare CALX & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | ICUI |
|---|---|---|
| Founded | 1999 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.6B |
| IPO Year | 2010 | 1992 |
| Metric | CALX | ICUI |
|---|---|---|
| Price | $54.47 | $148.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $77.75 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 799.0K | 224.4K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $933,685,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $21.58 | N/A |
| Revenue Next Year | $13.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.89 | N/A |
| 52 Week Low | $28.61 | $107.00 |
| 52 Week High | $71.22 | $175.51 |
| Indicator | CALX | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 60.78 |
| Support Level | $52.72 | $141.39 |
| Resistance Level | $56.60 | $148.55 |
| Average True Range (ATR) | 1.68 | 3.56 |
| MACD | 0.27 | -0.54 |
| Stochastic Oscillator | 42.09 | 77.08 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.